secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001601830-25-000164
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion appoints Najat Khan as CEO effective Jan 1, 2026; Q3 net loss $162.3M
-------------------------------------------------------------------------------

- Najat Khan succeeds Chris Gibson as CEO and President effective Jan 1, 2026; Gibson becomes Chairman.
- Khan's base salary set at $680K; receives $1M equity now and expected additional $7.5M equity.
- Q3 revenue $5.2M (down from $26.1M); net loss $162.3M (vs $95.8M); R&D spend $121.1M.
- Cash ~$785M as of Oct 9, 2025; runway through end-2027; raised $387.5M from ATM facility.
- Second microglia phenomap accepted by Roche/Genentech triggers $30M milestone; total partner payments exceed $500M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000164/0001601830-25-000164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000164/rxrx-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001601830-25-000164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer